Patient data is increasingly in the hands of for-profit industries. Insurance firms and other for-profit companies have been collecting patient data that yields important information that could be used to shape medical care and health policy.
App’s success leads Don Brown to embrace consumer market
After building and selling three companies and starting a fourth, Dr. Don Brown thought he had seen it all. Even so, he still gets an occasional surprise.Read More
Debunking medical myths all in a day’s work for IU’s Dr. Aaron Carroll
Carroll uses Twitter, a New York Times column, blog post, podcast, videos and books to publish his findings on just about any health issue he thinks needs explaining or correcting.Read More
Mucus may be gross, but we produce a lot of it. And new research is uncovering just how beneficial it is in the human body.
The spinoff, called Sexton Biotechnologies, has raised $5 million in outside investment and will spin off in October. The biotech develops cell and gene therapy tools used to grow cells for medical purposes.
Should you avoid red meat? No. Should you strive for 10,000 steps a day? Not unless you just want to. So says Dr. Aaron Carroll, a pediatrician and researcher at the Indiana University School of Medicine who sees it as his life’s calling to debunk what he considers health myths and weak medical research.
In recent months, the drugmaker has won federal approval to sell a drug called Emgality for two conditions: migraine pain and cluster headaches.
The trials, which will begin in 2020, are part of a sweeping, five-year, $42 million federal research program known as Implementing Genomics in Practice. The first trial will examine whether early access to patients’ genomic data can help with treatment of high blood pressure, hypertension and chronic kidney disease.
Dr. Rainer Fischer is giving up the roles of CEO and chief scientific officer, but will continue as senior executive for innovation and discovery.
For a startup that has raised an eye-popping $71 million in just three years, Outpost Medicine LLC likes to keep a low profile. The young company, which is developing drugs for urinary and gastrointestinal disorders, is headquartered in small, unmarked space at the Parkwood Crossing office complex on East 96th Street. It has issued only a […]
Increasingly, top researchers are questioning whether drugs such as Lantus from Sanofi, Levemir and Novolog from Novo Nordisk A/S, and Humalog from Eli Lilly and Co. are really needed for many patients.
The researchers are testing the effectiveness of a small, targeted molecule to prevent or reverse chemotherapy-induced peripheral neuropathy—a nerve problem that causes pain, numbness and tingling.
Look at the future prospects, not the losses, says the CEO of a newly listed Chinese biotech company that’s developing anti-cancer drugs with Indianapolis-based Eli Lilly and Co.
President Donald Trump is linking the drug prices Americans complain about to one of his longstanding grievances: foreign countries the president says are taking advantage of U.S. research breakthroughs.
The West Lafayette biotech firm’s stock traded as low as $1.41 last fall, following multiple setbacks and restructurings. But the stock had soared to $24 Thursday morning after news that it would be acquired by Novartis.
Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
The university said it has hired 33 research faculty to help under the “Grand Challenges” program in precision health, an initiative it rolled out two years ago.
Dr. Dan Skovronsky needs to deliver on the drugmaker’s audacious goal of launching 20 new medicines by 2023.
While the ultimate outcome remains far from certain, the study is a bright spot—if a tenuous one—in the search for a treatment for Alzheimer’s, where more than 100 experimental drugs have failed.
The pharmaceutical company said the 130,000-square-foot building will allow scientists to collaborate better on research for small molecules and synthetic peptides.
An independent data-monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease.